Toxicological Sciences
◐ Oxford University Press (OUP)
Preprints posted in the last 30 days, ranked by how well they match Toxicological Sciences's content profile, based on 41 papers previously published here. The average preprint has a 0.03% match score for this journal, so anything above that is already an above-average fit.
Hamed, K. J. A.; Bundid, R. M.; Sayah, M. A.; Gamal, M.; Taha, R. S. M.; Nuri, N.
Show abstract
Abstract Background. Acrylamide, a neurotoxicant in heated foods and smoke, is linked to occupational neuropathy, but evidence regarding chronic, low-level population exposure remains limited. We evaluated the association between acrylamide exposure biomarkers and peripheral neuropathy among U.S. adults. Methods. A total of 2,266 NHANES 2003-2004 participants (age >40) were analyzed. Exposure was assessed via hemoglobin adducts (HbAA/HbGA); neuropathy via monofilament testing >1 site). Survey-weighted logistic regression models adjusted for confounders. Sensitivity analyses included cubic splines, diabetes stratification, and multiple imputation. Results. Neuropathy prevalence was 15.5%. In adjusted models, neither adduct was associated with neuropathy (HbAA OR: 0.98, 95% CI: 0.82-1.17; HbGA OR: 0.91, 95% CI: 0.77-1.08). No dose-response gradient was observed. Expected risk factors (age, diabetes) showed strong associations, validating model sensitivity. The null result remained robust across sensitivity analyses, including a stricter outcome definition and multiple imputation (pooled OR: 0.97, 95% CI: 0.83-1.14). Conclusions. Acrylamide adducts were not associated with peripheral neuropathy in this national sample. General population levels (~55-70 pmol/g) lie well below established occupational no-observed-adverse-effect levels (~510 pmol/g) and clinical neuropathy thresholds (~6,000 pmol/g), providing a mechanistically coherent explanation for this null result.
Kim, C.; Tagmount, A.; Zhu, Z.; Barbazuk, W. B.; Bacher, R.; Vulpe, C. D.
Show abstract
Hexafluoropropylene oxide dimer acid (GenX), a replacement for legacy per- and polyfluoroalkyl substances (PFAS), is increasingly detected in the environment, yet its chronic toxicity remains poorly characterized. Current safety assessments rely largely on short-term, high-dose studies that may not capture the biological consequences of long-term, low-dose exposure. To address this gap, we employed 3D human liver (HepG2/C3A) spheroids cultured in a continuously rotating bioreactor system (ClinoStar) to systematically evaluate dose- and time-dependent mRNA changes in response to GenX under environmentally relevant conditions. Spheroids were exposed to GenX (0.08-50 M, spanning environmentally relevant to mechanistically informative concentrations) for acute (4 days) and chronic (4 weeks) durations, followed by genome-wide TempO-Seq transcriptomic profiling and benchmark dose (BMD) modeling. GenX elicited pronounced non-monotonic mRNA changes in acute exposure conditions, with the greatest number of differentially expressed genes (DEGs) observed at an intermediate concentration (0.4 M). In contrast, chronic exposure exhibited a generally concentration-dependent increase in DEGs, except for the 10 M condition, indicating a more consistent dose-response relationship than acute exposure. Notably, acute and chronic exposures elicited qualitatively distinct mRNA changes with low concordance across matched concentrations, demonstrating that exposure duration was a major determinant of mRNA changes. Acute low-dose GenX exposure preferentially modulated mRNA encoding components of cell cycle-related pathways, whereas acute higher dose exposures suppress mRNA levels of the constituents of lipid metabolic pathways and increase expression of mRNA encoding proteins involved in stress- and toxicity-associated signaling. Chronic exposure revealed a different pattern of changes in mRNA expression not observed under acute exposure conditions, including suppression of cellular components involved in lipid-related pathways at the lowest concentration tested. At higher concentrations, mRNA levels of components of multiple metabolic pathways were altered. Benchmark dose modeling identified a significantly lower transcriptomic point of departure (tPOD) for chronic exposure as compared to acute exposure, suggesting increased cellular sensitivity to prolonged GenX exposure and supporting the relevance of chronic models for human exposure assessment. Collectively, these findings demonstrate that GenX elicits time-dependent and non-monotonic changes in mRNA levels of human liver (HepG2/C3A) spheroids, with distinct responses depending on the exposure duration and dose. This study, therefore, highlights the importance of incorporating chronic, human-relevant in vitro models and transcriptomic endpoints into PFAS risk assessment and suggests that conventional short-term assays may underestimate the biological impact of sustained low-dose exposure. Key message (Impact of the study)This study provides systematic comparisons of short term (4 day) versus longer term (4 weeks), environmentally relevant GenX exposure in human liver spheroids, revealing non-monotonic, time-dependent changes in mRNA levels encoding cellular components of lipid metabolism-related pathways with potential implications for appropriate dose and time exposure parameters for use in New Approach Methods to be applied in risk assessment.
Afzal, Z.; Hatcher, C.; Kumar, D.
Show abstract
Microcystin-LR (MC-LR), a cyanobacterial toxin produced during harmful algal blooms, is an increasing environmental and public health concern as the frequency and intensity of harmful algal blooms continue to rise globally. While the effects of MC-LR have been extensively studied in young organisms, much less is known about how aging influences susceptibility to cyanotoxin exposure. Here, we used the naturally short-lived turquoise killifish, Nothobranchius furzeri, to investigate transcriptional responses to low-level MC-LR exposure in a senescent vertebrate. Approximately 8-month-old GRZ killifish were exposed to a low dose of 0.5 g/L MC-LR, followed by whole-body RNA sequencing and sex-stratified differential expression analysis. Despite identical experimental conditions and exposure, males and females exhibited strikingly distinct transcriptional responses, with 313 differentially expressed genes (DEGs) in males and 263 in females and only 27 DEGs shared between the sexes. Among the shared responses, pck1, a key regulator of gluconeogenesis, was strongly downregulated in both sexes, accompanied by altered expression of genes associated with mitochondrial function, metabolic regulation, extracellular matrix remodeling, and genome maintenance. Males exhibited prominent remodeling of skeletal muscle and contractile programs, supported by enrichment of sarcomeric, myofilament, and contractile-fiber-associated genes. In contrast, females showed pronounced alterations in reproductive and metabolic programs, including vitellogenin- and zona pellucida-associated transcripts. Cell/tissue associated marker-module analysis further revealed distinct sex-dependent shifts in structural, neural, immune, metabolic, and reproductive transcriptional signatures. Together, these findings demonstrate that MC-LR elicits a broad but strongly sex-dependent transcriptional response in senescent N. furzeri, involving responses in multiple physiological systems. Our study identifies biological sex as an important determinant of cyanotoxin responses in an aging context and establishes naturally aged N. furzeri as a tractable vertebrate model for investigating interactions between environmental exposure and biological aging.
Phelps, S. E.; Chernick, M.; Huayta, J.; Webster, A.; Joyce, A. S.; Ettinger, K. M.; Beggs, C.; Zibo, S.; Ferguson, L.; Di Giulio, R. T.; Meyer, J. N.; Jayasundara, N.
Show abstract
Typical environmental exposures to the toxic class of chemicals known as polycyclic aromatic hydrocarbons (PAHs) involve complex mixtures; however, relatively few mechanistic toxicity studies have evaluated them as environmental mixtures, instead focusing on individual compounds or simple mixtures. In this study, we first derived Republic Sediment Extract (REPSE), a complex PAH mixture extracted from sediment at the Republic Creosoting site of the Elizabeth River in Norfolk, Virginia. After characterizing the PAH contents of REPSE, we evaluated its mechanisms of developmental neurotoxicity in three evolutionarily distinct taxa, leveraging the unique strengths of Atlantic killifish, zebrafish, and Caenorhabditis elegans as model species, with a focus on the Aryl hydrocarbon Receptor (AhR) pathway. Embryonic REPSE exposure caused induction of CYP1A in both fish species at sub-teratogenic concentrations, consistent with activation of the canonical AhR pathway. These sub-teratogenic exposures nevertheless induced neurotoxicity across both fish species, altering neurobehavioral phenotypes in fish, and induced dopaminergic neuronal damage in worms, again at non-teratogenic concentrations. To determine whether these effects were linked to canonical AhR response pathways, we examined killifish offspring from the pollution-adapted Republic Creosoting population, which exhibited characteristic recalcitrance to CYP1A induction, but remained susceptible to the neurobehavioral effects of REPSE. The induction of neuronal damage in worms provides orthogonal evidence for a non-AhR mechanism, because C. elegans AhR is not transcriptionally activated by PAHs as in vertebrates. Further probing of potential mechanisms underlying REPSE-induced neurotoxicity in worms revealed altered neuronal redox status (roGFP) and energy availability (ATP:ADP ratio). Collectively, our multispecies approach reveals conserved mechanisms of PAH mixture neurotoxicity, including effects that extend beyond canonical AhR signaling.
Howard, B. E.; Mav, D.; Balik-Meisner, M.; Phadke, D.; Green, A. J.; Truong, L.; Tanguay, R. L.; Shah, R. R.
Show abstract
BackgroundZebrafish (Danio rerio) are a powerful vertebrate model for developmental toxicology and chemical safety assessment, yet large-scale transcriptomics in zebrafish remains limited by cost and data heterogeneity. Targeted transcriptomics offers a cost-effective alternative, but gene extrapolation methods tailored to zebrafish have not been systematically developed or evaluated. ObjectivesWhile the S1500+ platform is widely used for toxicogenomics research with rat, mouse, and human cell lines as model systems, its use in zebrafish has been limited due to data scarcity and lack of suitable bioinformatics approaches for analysis of such data. To that end, we sought to (i) curate a large zebrafish transcriptomic training data resource, and (ii) evaluate multiple machine learning strategies for reconstructing unmeasured transcriptome-wide expression profiles for data originating from the zebrafish-specific reduced representation gene set ("Zf S1500+"). MethodsWe assembled 14,924 zebrafish RNA-Seq samples covering 21,930 genes across 1,246 studies. Using the Zf S1500+ gene subset (3,062 genes), we trained and tested three extrapolation approaches: principal components regression (PCR), a locally weighted extension of PCR (PCR+), and a neural network mixture-of-experts model (NN-MoE). Model performance was assessed using mean absolute error (MAE), mean squared regression error (MSRE), and weighted variants of these metrics. ResultsExtrapolation performance using the baseline approach was strongly influenced by tissue and developmental context, with within-tissue models outperforming cross-tissue models. Errors were lowest when training and testing were conducted within the same tissue or between developmentally related tissues. Both PCR+ and NN-MoE improved upon the baseline PCR approach, with NN-MoE reducing average MAE by [~]20% and MSRE by [~]17%. Importantly, extrapolation remained reliable for the majority of genes, even when limiting output to high-confidence predictions using an empirical MAE threshold. ConclusionsWe demonstrate that targeted transcriptomics can be effectively extended to zebrafish, enabling robust transcriptome-wide extrapolation at reduced cost. The NN-MoE method provided the most substantial gains, highlighting the value of non-linear and ensemble modeling in heterogeneous datasets. These results establish a scalable framework for zebrafish toxicogenomics and suggest that accuracy will continue to improve with larger, better-annotated datasets, paving the way for broader application in chemical safety assessments.
Leheup, M. F.; Johnson, G.; Kirkland, D.; Pasello dos Santos, F.; Mueller, S.; Weaver, R.; Griffon, A.
Show abstract
The presence of N-nitrosamine drug substance-related impurities (NDSRIs) in pharmaceuticals represents a significant regulatory and safety challenge due to their classification as "cohort of concern" compounds. This paper describes the toxicological evaluation of N-Nitrosotrimetazidine (NTMZ), performed to refine the initial default acceptable intake (AI) limits of 18 to 26.5 ng/day established by regulatory authorities. The evaluation followed a tiered approach: NTMZ was first confirmed as mutagenic in vitro via the standard Ames test. To further investigate its genotoxic potential, two in vivo studies were conducted in Wistar and transgenic rats. Detection of DNA strand breaks in the liver and duodenum (comet assay) together with positive results in the cII mutation assay confirmed an in vivo mutagenic mode of action. Benchmark Dose (BMD) analysis of the transgenic rat data yielded a BMDL50 of 7 mg/kg/day in the male liver. To characterize long-term carcinogenic risk, a GLP-compliant 2-year carcinogenicity study was conducted in Wistar rats. Chronic exposure induced dose-dependent increases in liver tumors (hemangiosarcomas, hepatocellular carcinomas and adenomas) and intestinal tumors (adenomas and adenocarcinomas), leading to a Tumor Dose 50 (TD50) of 23 mg/kg/day in male rats. Benchmark dose analysis of tumor incidence identified a lowest BMDL10 of 2.6 mg/kg/day in females, which served as the basis for deriving an AI of 13 microg/day. This assessment demonstrates a strong predictive correlation between the BMD derived from the in vivo transgenic model, the BMDL10 and the final TD50 values obtained in the 2-year carcinogenicity study. These findings provided the scientific basis for establishing a conservative AI of 13 microg/person/day based on the BMDL10 and further support the regulatory acceptance and use of BMD-derived approaches for the evaluation of nitrosamine impurities.
van Kessel, H. W.; Wedler, M.; Helmke, P.; Zigure, D.; Ferguson, S. S.; Harrill, J.; Ecker, G.; Liu, S.; Oelgeschläger, M.; Callegaro, G.; van de Water, B.
Show abstract
Integrating high-throughput in vitro data into next-generation risk assessment (NGRA) workflows requires screening strategies that yield quantitative potency estimates and mechanistically interpretable biological signals. Transcriptomic and morphological profiling are increasingly adopted for early-stage hazard identification by enabling triage of substances for resource-intensive follow-up and prioritizing candidates most likely to present meaningful risk. In this study, we aimed to characterize biological concordance and uncertainty by quantifying how well high-throughput transcriptomics (HTTr) and Cell Painting PLUS (CPP) bioactivity profiles recover target-relevant biological signals in immortalized human renal proximal tubule epithelial RPTEC/TERT1 cells using 313 reference chemicals with high-confidence target annotations. Through quality control procedures and biological activity filters we yielded 142 reference chemicals spanning 66 different targets, which were systematically evaluated for biological concentration-responses by HTTr and CPP. HTTr was evaluated using TXG-MAPr-based qualitative and quantitative gene network activity analysis. HTTr showed the most prominent activity for targets that were highest expressed in RPTEC/TERT1 cells. Active chemical-pairs showed strong gene network activity correlation albeit with different potencies. Similarly, the highest transcriptomic concordance was observed for reference chemicals acting in the same pathway, such as EGFR/MEK or PI3K/AKT/mTOR. CPP often showed high sensitivity primarily at the organelle level providing limited statistical power for chemical grouping. Collectively, the results support HTTr and CPP as complementary early-tier assays within an in vitro weight-of-evidence safety testing framework. Although CPP is suitable as a cost-effective screening modality, HTTr offers higher mechanistic resolution for mode-of-action inference in high-throughput bioactivity screening and therefore remains necessary for high-confidence mechanistic interpretation.
Yamashita, A.; Kasai, H.; Aoyagi, H.; Wakae, K.; Kobayashi, K.; Miyajima, A.; Higuchi, Y.; Suemizu, H.; Fukushima, R.; Isogawa, M.; Wakita, T.; Aizaki, H.; Moriishi, K.
Show abstract
Background & AimsCurrent nucleos(t)ide analogs efficiently suppress hepatitis B virus (HBV) replication but have limited effects on viral transcription from covalently closed circular DNA (cccDNA) and integrated HBV DNA. We aimed to identify clinically applicable compounds that directly inhibit HBV transcription by screening FDA-approved drugs. Approach & ResultsScreening of 1,470 FDA-approved compounds using an HBV enhancer I/X promoter reporter system identified vorapaxar and aripiprazole as potent inhibitors of viral promoter activity. Both compounds suppressed HBV replication in HBV-producing cells, HBV-infected HepG2-hNTCP cells, and primary human hepatocytes. Aripiprazole reduced hepatocyte nuclear factor 4 (HNF4) protein levels through an ERK/JNK-dependent pathway and inhibited HBV core promoter activity, whereas vorapaxar acted independently of HNF4. Both compounds suppressed enhancer I/X promoter activity through inhibition of STAT3 signaling. Vorapaxar inhibited PAR-1-mediated SRC, EGFR, and STAT3 activation, while aripiprazole suppressed SRC-STAT3 signaling independently of EGFR. PAR-1 activation enhanced HBV transcription, whereas PAR-1 knockdown reduced promoter activity and viral RNA expression. Both compounds also reduced HBV replication in human liver chimeric mice at clinically relevant exposure levels without apparent severe toxicity. ConclusionsVorapaxar and aripiprazole suppress HBV transcription and replication through distinct host signaling pathways. These findings identify PAR-1-STAT3 signaling as a previously unrecognized regulator of HBV transcription and suggest that host-targeting approaches may complement current therapies by suppressing viral gene expression from both cccDNA and integrated HBV DNA. Impact and implicationsCurrent nucleos(t)ide analogues effectively suppress HBV reverse transcription but have limited effects on viral transcription from cccDNA and integrated HBV DNA, highlighting the need for therapies targeting viral gene expression. We identify PAR-1- STAT3 signaling as a previously unrecognized regulator of HBV transcription and demonstrate that two clinically approved drugs, vorapaxar and aripiprazole, suppress HBV replication through distinct host signaling pathways. These findings are relevant to researchers developing host-targeting antivirals and to clinicians seeking complementary therapeutic strategies beyond current nucleos(t)ide analogue therapy. Although further clinical validation and combination studies are required, our results provide a rationale for repurposing approved drugs and for developing transcription-targeting therapies that may complement existing treatments for chronic hepatitis B. HighlightsO_LIVorapaxar and aripiprazole suppress HBV through distinct host pathways. C_LIO_LIBoth drugs inhibit HBV replication in vitro and in humanized liver mice. C_LIO_LIPAR-1 inhibition reduces HBV transcription by blocking SRC/EGFR/STAT3 signaling. C_LIO_LIPAR-1-STAT3 signaling is a novel regulator of HBV transcription. C_LIO_LIHost-targeting antiviral therapy complements current HBV treatment. C_LI
Thomas, M. E.; McLean, Z. S.; Belcher, S. M.
Show abstract
Per-and polyfluoroalkyl substances (PFAS) constitute a diverse class of persistent synthetic chemicals utilized across industrial, medical, and consumer sectors that are pervasive global pollutants. Exposure to PFAS is linked to adverse impacts on both innate and adaptive immune systems. Human lactoferrin (hLF) is a key antimicrobial component of the developing innate immune system present in colostrum and breast milk. We hypothesized that hLF is a potential PFAS binding protein related to PFAS immunotoxicity. The results of thermal stability experiments indicated that all 11 tested PFAS bind and destabilize the structure of hLF. Notably PFBA, PFOS, HFPO-DA, and 6:2 FTSA decreased apo-hLF melting temperatures from 64oC to [≤] 37oC, suggesting that PFAS exposures destabilize the native hLF protein under physiological conditions. Relative binding affinities (Kd) ranged from 0.2-11 mM across tested PFAS. Molecular docking was used to confirm experimental binding affinities and identify molecular interactions involved with PFAS binding. Calculated Gibbs Free Energies of binding ranged from -4.4 to -8.8 kcal/mol. Together, these results demonstrate that PFAS bind hLF at affinities comparable to human serum albumin and other PFAS binding proteins, and that some PFAS can destabilize hLF protein structure at physiologically relevant temperatures and conditions.
Meda, C.; Dolce, A.; Talamazzini, G.; Ohlsson, C.; Carli, F.; Infelise, P.; Gastaldelli, A.; Maggi, A.; Della Torre, S.
Show abstract
Background and AimsPregnancy requires dynamic, stage-specific adaptations in maternal liver metabolism and growth to sustain fetal development while preserving systemic homeostasis. Estrogen signaling, which significantly increases during pregnancy, is primarily mediated in hepatocytes by estrogen receptor (ER). Although hepatic ER regulates female liver metabolism under non-pregnant conditions, its role in pregnancy-induced hepatic remodeling remains unclear. MethodsWe studied non-pregnant and pregnant control and liver-specific ER knockout (LERKO) mice across gestational stages using longitudinal physiological measurements, liver transcriptomics, targeted metabolomics, histological assessment of cell proliferation, and metabolic phenotyping. ResultsIn control mice, pregnancy elicited sequential hepatic remodeling characterized by early induction of cell-cycle programs, a mid-gestational peak in hepatocyte proliferation with transient suppression of selected metabolic pathways, and late reactivation of specific metabolic programs. Chronic hepatic ER deficiency alters this temporal pattern. LERKO livers showed premature activation of proliferative and anabolic transcriptional programs, changes in amino acid- and fatty acid-related metabolic pathways, and altered temporal regulation of AKT-mTORC1-related signaling. At mid-gestation, LERKO mice displayed reduced hepatocyte proliferation, altered expression of metabolic and insulin-related genes, blunted gestational glucose adaptation without overt evidence of systemic insulin resistance, and changes in the light/dark-phase metabolic patterns. ConclusionsThese findings suggest that hepatic ER is required for the appropriate stage-specific coupling of liver growth, metabolic remodeling, and insulin-responsive signaling during pregnancy. Its loss is associated with gestational hepatic maladaptation and systemic metabolic phenotypes, providing a framework for investigating estrogen-dependent mechanisms underlying pregnancy-associated metabolic and liver disorders. HighlightsHepatic ER is required for stage-specific liver remodeling during pregnancy. Loss of hepatic ER alters temporal coupling of liver growth and metabolism. LERKO mice show early changes in amino acid- and fatty acid-related pathways. Hepatic ER loss reduces proliferation and alters gestational glucose adaptation. Hepatic ER loss is associated with altered light/dark-phase metabolic organization. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=80 SRC="FIGDIR/small/743939v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@d52bborg.highwire.dtl.DTLVardef@b27511org.highwire.dtl.DTLVardef@23b286org.highwire.dtl.DTLVardef@19d9314_HPS_FORMAT_FIGEXP M_FIG C_FIG
Young, A. S.; Campbell, K. A.; Everson, T. S.; Gennings, C.; Braselton, M. E.; Mullins, C. E.; Jariwala, P.; Smith, A. K.; Spencer, J. B.; Hipp, H.; Gaskins, A. J.; Walker, D. I.
Show abstract
Endocrine-disrupting chemicals can target ovaries and interfere with key milestones of reproduction. Previously, we found that mixtures of the chemical exposome measured in follicular fluid (FF) were cumulatively associated with lower oocyte yield. Because ovaries age faster than many other organs, our current aim was to evaluate associations of FF chemical mixtures with epigenetic age acceleration and epigenetic pathways in FF cells. FF was collected during oocyte retrieval from 76 patients undergoing assisted reproduction in Atlanta. The exposome was measured using untargeted high-resolution mass spectrometry with gas (GC) and liquid (LC) chromatography. Weighted quantile sum (WQS-RS) indices were constructed for three mixtures of chemicals in association with oocyte yield, separated by instrument configuration (GC, LC-HILIC, LC-C18). DNA methylation was measured from the cellular component of FF using Illumina MethylationEPIC BeadChip, with age acceleration based on the GrimAge clock. Regression and pathway enrichment analyses elucidated relationships between chemical exposures or mixture indices and epigenetic markers, adjusted for age and technical covariates. All three chemical mixture indices were associated with epigenetic age acceleration in FF (p<0.05). For example, a standard-deviation increase in the GC-detected mixture was associated with 0.23 standard-deviations higher accelerated aging (95% CI: 0.0058-0.45; p=0.048). Twenty-seven frequently detected chemicals, including benzo[a]pyrene, plasticizers, flame retardants, forever chemicals, and pesticides, were associated with epigenetic pathways related to ovarian follicle growth and hormone signaling (p<0.05; six under false discovery rate<5%). In summary, environmental chemicals may accumulate in ovaries, contribute to accelerated epigenetic aging of ovarian somatic cells, and potentially affect follicle development.
Ye, X.; Burrows, A. C.; Horak, A. J.; Wang, Z.; Obringer, E.; Roth, K.; Petriello, M. C.; Brown, J. M.
Show abstract
BackgroundEmerging evidence suggests that PFAS can cross blood-brain barrier and lead to neurotoxicity. Recent evidence also suggest that PFAS can bioaccumulate in gut microbiota resident in the gut. However, how gut microbes influence PFAS-driven reorganization of metabolic homeostasis in the brain is poorly understood. MethodsTo address this gap, we investigated how gut microbiota influences brain metabolomic and lipidomic responses to PFAS exposure. Specific pathogen-free (SPF) and germ-free (GF) mice were fed an obesogenic diet for 8 weeks to promote metabolic disturbance. After 1 week of acclimation, half received control water and half received water containing a PFAS mixture (PFHxS, GenX, PFOA, PFOS, and FTOH mixture). Plasma and brain samples (cortex, subcortex, cerebellum, olfactory bulb, and brainstem) were collected after 8 weeks. Untargeted analyses were performed for lipidomic, metabolomic and PFAS using high resolution liquid chromatography tandem mass spectrometry (LC-MS/MS). Data was processed using MassCube with open-sources libraries. ResultsPFHxS, GenX, PFOA, PFOS, PFDA, and PFDS were detected in plasma. PFHxS, PFOA, PFOS, and PFDS were detected across all five brain regions, with PFOS as the predominant brain-enriched species. Pathway analysis identified nicotinate and nicotinamide metabolism as the most consistently PFAS-altered pathway in both SPF and GF mice. PFAS exposure induced region-specific metabolic remodeling, with gut microbiota differentially modulating responses in the cortex, cerebellum, and brainstem, whereas the olfactory bulb showed a largely microbiota-independent response. In addition to local effects within individual brain regions, plasma-brain analysis suggested systemic metabolic responses across tissues, with association strength varying by brain region and microbiome status. Gut microbiota also shaped PFAS-induced lipid dysregulation in the brain, and methylnicotinamide and delta-valerobetaine were among the most responsive metabolites. ConclusionThis study is the first to demonstrate that resident microbiota impact PFAS-associated metabolic remodeling across the gut-plasma-brain axis. HighlightsO_LIPFAS-induced metabolic remodeling in the brain is modified by gut microbiota. C_LIO_LIPFAS exposure alters nicotinate and nicotinamide metabolism throughout the brain. C_LIO_LIPFAS-induced brain metabolic responses are region specific and microbiota dependent. C_LIO_LIPlasma-brain analysis suggests potential systemic metabolic disruption by PFAS. C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/743341v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@15301deorg.highwire.dtl.DTLVardef@9fac0aorg.highwire.dtl.DTLVardef@d7f0f4org.highwire.dtl.DTLVardef@10c29c2_HPS_FORMAT_FIGEXP M_FIG C_FIG
Henseler, D.; Aruna, O. A.
Show abstract
2,4-Dinitrochlorobenzene (DNCB) is a well-characterized skin sensitizer that has been widely used in immunological and toxicological research and, historically, in clinical immunotherapy. Although it is a well-investigated chemical, this is the first study focusing on the dose response behavior at low-level concentrations. The aim was to reveal potential hormetic effects due to its known Nrf2 inducting activity. Therefore, THP-1 cells were treated with low doses of DNCB and two endpoints were evaluated for hormetic responses: metabolic activity using a resazurin-based assay and immune activation by measuring CD86 and CD54 expression using flow cytometry. The results showed a significant hormetic effect on the metabolic endpoint at the lower cell density for both analyzed time points, and a hormetic tendency at the higher cell density. Metabolic activity increased to approximately 125% of the control at 0.05 micromolar DNCB. For the immunological endpoint a slight decrease in CD86 and CD54 surface marker expression was observed, up to -16% and up to -12% compared to control at 0.5 micromolar DNCB. These findings highlight the importance of including low dose concentrations when characterizing chemical dose-response relationships and evaluating toxicological risk.
Jesikeiwicz, L.; Marathe, R.; Sepehri, B.; Demissie, R.; Lee, H.; Veiga-Lopez, A.; Villegas, J. A.
Show abstract
Chemical exposures during pregnancy are linked to an increased risk of pregnancy complications that contribute significantly to maternal and infant morbidity and mortality and can lead to long term health consequences for both the mother and the offspring. The placenta, a central regulator of pregnancy health, is a direct target of environmental toxicants. Epidermal growth factor receptor (EGFR), highly expressed in the placenta, regulates proliferation, migration, invasion, fusion, and cellular bioenergetics. To identify compounds of environmental concern with potential for EGFR-disrupting activity, we optimized a high-throughput virtual screening protocol for the identification of EGFR inhibitors and achieved enrichment factors of EF1% = 10.09, EF5% = 3.86, and EF10% = 3.0 in a benchmarking dataset. We applied this protocol to screen the Collaborative Estrogen Receptor Activity Prediction Project database, finding that top-scoring compounds were enriched for aromatic and fused-ring chemical classes, including dyes. Kinase activity assays revealed that two out of thirteen selected compounds, Vat Red 32 and Reactive Red 136, inhibited EGFR kinase activity with micromolar IC50 values. Additionally, pose refinement with molecular dynamics simulations characterized the binding interactions of Reactive Red 136 within the EGFR kinase domain, and functional assays in HTR-8/SVneo placental trophoblast cells showed that Reactive Red 136, but not Vat Red 32, partially attenuated EGF-mediated cell migration despite both compounds inhibiting EGFR kinase activity. Together, this study has generated an enriched dataset of candidate environmental EGFR modulators, with experimental validation confirming enrichment for EGFR-disrupting activity among the selected compounds. These results provide a valuable resource for toxicological studies.
Ledue, E. L.; Adelman, N. E.; Lorenger, M. K.; Wagner, D. J.; Trafton, S. K.; Biro, E.; Morrison, E. R.; D'Alessio, Q. W.; Burnell, J. E.; Gosse, J. A.
Show abstract
People are widely exposed to the antimicrobial cetylpyridinium chloride (CPC) via consumer products, but CPC is a mitochondrial toxicant with potency comparable to that of canonical mitotoxicants. CPC is largely unregulated despite growing usage, bioavailability, and ability to cross the blood-brain barrier. Previously, we showed, in several cell types at non-cytotoxic and exposure-relevant doses, CPC inhibits ATP and OCR, endpoints of the electron transport chain (ETC). Mitochondrial toxicity is linked to multiple diseases (e.g., diabetes, Parkinsons, myalgic encephalomyelitis), but CPC has not been studied epidemiologically, and little mechanistic information is available. To determine why OCR and ATP are hampered by CPC, we hypothesized that CPC inhibits individual ETC components, cardiolipin, or TCA enzymes. Here, we show that, in primary human skin cells, an immune mast cell model, and isolated mitochondria, CPC apparently inhibits multiple ETC Complexes. Detailed investigation pinpointed the mechanism to the distal end of ETC: Complex III-cytochrome C-Complex IV. Using multiple approaches, we show that CPC does not directly inhibit any of the Complexes (not even Complex I as earlier reported), nor TCA enzymes, nor coenzyme Q. Yet, we found that CPC exhibits mitotoxicity as potent as cyanide. Anionic lipid cardiolipin attracts cytochrome C to the inner mitochondrial membrane so that it may shuttle electrons from Complex III to IV. Despite not altering levels of cardiolipin, CPC hinders cytochrome C by electrostatically interfering with cardiolipin. To aid epidemiology, risk analysis, and predictive toxicology, we have determined the precise biochemical mechanism of action of this ubiquitous compound.
Taffe, M. A.; Kim, H. S.; Doran, T. A.; Coons, T. R.; Rahman, S. R.; Grant, Y.; Vandewater, S. A.
Show abstract
Background: The nicotine analog 6-methyl nicotine (6-MN) has appeared in commercial e-cigarette liquids, and other products, spurring interest in determining the extent to which it conveys similar effects to those of nicotine. Objective: To determine if 6-MN acts like nicotine to decrease body temperature, decrease nociception, suppress wheel activity and reinforce operant behavior when delivered by vapor inhalation using an Electronic Nicotine Delivery System (ENDS; "e-cigarette") approach in a rat model. Methods: Male and female (N=8 per sex) young adult Sprague-Dawley rats were evaluated for rectal temperature and nociceptive responses (warm water tail-withdrawal) to the inhalation of vapor from (-)-6-MN or (-)-nicotine in concentrations ranging from 5-30 mg/mL in the propylene glycol vehicle. Rats were then assessed for the reinforcing effects of nicotine and 6-MN using a vapor self-administration procedure and the rate suppressing effects of nicotine and 6-MN on wheel activity following injection. Results: Inhalation of nicotine or 6-MN for 30 minutes decreased the rectal temperature and increased tail-withdrawal latency of female and male rats in a concentration-dependent manner. The magnitude of the effects of 6-MN and nicotine were similar at similar vapor concentrations. Operant responding for 6-MN vapor was increased by pre-treatment with the antagonist mecamylamine. 6-MN was more potent than nicotine at suppressing wheel activity after injection. Conclusions: 6-MN induces effects very similar to those of nicotine, at a similar potency when inhaled and at a slightly increased potency when injected.
DeTemple, E. R.; Jackson, C. E.; Schultz, A.; Hampton, T. H.; Shaw, J. R.; Chowdhury, P. R.
Show abstract
Inorganic arsenic is a widespread environmental contaminant and known human carcinogen, yet the mechanisms by which nutritional status modulates arsenic toxicity remain poorly understood. Here, we investigated the main and interactive effects of environmentally relevant concentrations of arsenic, low food quantity, and low dietary phosphorus supply on genome-wide gene expression in aquatic grazer Daphnia pulex. Differential gene expression analysis identified a total of 1,213 differently expressed genes with interactions of arsenic x nutrient stressors accounting for approximately 70% of the transcriptomic response. Low phosphorus emerged as a dominant main effect stressor and it also had a profound impact on transcription as a co-stressor. The low phosphorus x arsenic interaction exhibited the greatest transcriptional impact (435 DE genes), revealing that phosphorus limitation rather than food quantity influences arsenic toxicity at the gene expression level. Gene ontology and Pathway Activation Analysis revealed that main effects elicited simple yet distinct functional responses, whereas arsenic x nutrient interactions induced complex pathway-level disruptions including cell signaling, detoxification metabolism, DNA repair mechanisms, and energy homeostasis. Further assessment of gene expression revealed that all arsenic x nutrient interactions are antagonistic supporting previous literature that found arsenic behaves antagonistically as a co-stressor. Our results provide mechanistic insight into how nutritional status modulates arsenic toxicity and highlights the importance of considering arsenic x nutrient co-stressor interactions.
Gao, Y.; Zhang, Z.; Li, Y.; Qiu, J.
Show abstract
Long-term in vivo transcriptomic time courses are costly, limiting assessment of chronic molecular responses from short studies. We developed a pharmacokinetics-informed transcriptomic ordinary differential equation model (PKT-ODE) that links an oral pharmacokinetic profile and Hill drug-effect function to first-order turnover of co-expression modules. The model was fitted to rat liver responses to fenofibrate at three doses in Open TG-GATEs through day 8. At the held-out day-29 endpoint, PKT-ODE achieved Pearson r = 0.960 and mean squared error (MSE) = 0.148. In this dataset, these values achieved lower prediction error and higher correlation than four statistical baselines and validation-selected linear and multilayer-perceptron transition models. Literature-curated peroxisome proliferator-activated receptor target genes occurred only in modules with positive fitted drug effects. These results provide a proof of concept for pharmacokinetics-informed transcriptomic extrapolation; cross-compound, cross-organ and alternative-regimen performance remain to be tested.
Meng, F.; Xin, H.; Li, R. R.
Show abstract
Objective White smoke inhalation injury (WSI) causes severe acute lung damage with no specific therapy currently available. Sphingolipid metabolism is implicated in pulmonary inflammation, but its transcriptional regulatory landscape in WSI remains unexplored. This study aimed to identify key sphingolipid metabolism related genes and evaluate their regulatory roles and therapeutic potential in WSI. Methods We established a rat model of WSI and performed integrated bulk RNA sequencing, weighted gene coexpression network analysis (WGCNA), and single-cell RNA sequencing (scRNAseq) to screen for differentially expressed sphingolipid metabolism-related genes (DESRGs). Protein-protein interaction (PPI) network with four centrality algorithms was used to prioritize hub genes. In silico gene knockout and molecular docking were conducted to assess regulatory functions and identify potential drug candidates. Results We identified 22 DESRGs that were predominantly enriched in DNA replication and cell cycle pathways rather than canonical sphingolipid metabolic processes. PPI consensus prioritized three hub genes--Top2a, Ttk, and Ccna2--with Top2a exhibiting the highest expression in epithelial cells and significant downregulation after smoke exposure. ScRNAseq revealed immune cell infiltration and epithelial differentiation trajectories. Virtual knockout showed that Top2a depletion affected the largest transcriptomic fraction (~0.4%) and was enriched in lysosome biogenesis, innate immunity, phagocytosis, and lipid catabolism. Molecular docking identified thalidomide as a high affinity ligand for Top2a (Vina score: -8.5 kcal/mol). Conclusion Our multiomics integrative framework identifies Top2a as a central regulatory hub linking sphingolipid associated inflammation to epithelial responses in WSI, and nominates thalidomide as a potential drug repurposing candidate. These findings provide prioritized targets for future translational investigation.
Hoyle, H. W.; Frank, A. K.; Amundsen-Isaksen, E.; Peisl, S.; Hovland, O. O.; Yeoh, J.; Selvarajah, M.; Aizenshtadt, A.; Hirayama-Shoji, K.; Sampaziotis, F.; Karlsen, T. H.; Busek, M.; Krauss, S.; Melum, E.
Show abstract
Background and aims Model systems for bile duct disorders are needed for testing therapeutic interventions. Current models have poor human relevance or limited potential for recreating the complex bile duct microenvironment at scale. We aimed to generate a humanized microphysiological system to model and treat cholangiopathies. Methods An in vitro bile duct was created using 3D printed microfluidic chips containing a collagen-embedded canal seeded with patient-derived primary human cholangiocytes. Barrier permeability and compound transport across the epithelium was measured, and disruption of the barrier was performed with lipopolysaccharide treatment. The duct was challenged with the known hepatotoxicant Chlorpromazine. Biliatresone was used to model biliary-atresia and treated using N-acetyl-L-cysteine. Results Cholangiocytes in the bile duct chip established a tight, polarized epithelial barrier. Verapamil and Linerixibat inhibited transport of rhodamine 123 and cholyl-lys-fluorescein respectively with 66 % (p = 0.0004) and 57 % (p = 0.03) reduction. 10 g/mL lipopolysaccharide led to a loss of epithelial barrier integrity, measured by an increase of over 1000 % in leakage of both 3 kDa (p = 0.0002) and 10 kDa dextran (p = 0.0001) along with upregulation of cytokines. Chlorpromazine displayed dose-dependent toxicity with EC50 values of 84, 140 and 96 M for three patient lines. Biliatresone induced a dose-dependent abnormal phenotype with loss of viability. The induced phenotype could be treated with N-acetyl-L-cysteine, improving viability from 23 % to 59 % (p < 0.0001) with treatment of 2 g/mL Biliatresone. Conclusions Our novel platform allows complex studies of bile duct biology, testing of off-target effects from drugs and treatment of a disease phenotype.